93 related articles for article (PubMed ID: 36362028)
21. Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer.
Sradhanjali S; Reddy MM
Curr Top Med Chem; 2018; 18(6):444-453. PubMed ID: 29788890
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia.
Sugden MC; Holness MJ
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):151-65. PubMed ID: 12476789
[TBL] [Abstract][Full Text] [Related]
23. Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways.
Lee EH; Chung JW; Sung E; Yoon BH; Jeon M; Park S; Chun SY; Lee JN; Kim BS; Kim HT; Kim TH; Choi SH; Yoo ES; Kwon TG; Kang HW; Kim WJ; Yun SJ; Lee S; Ha YS
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362028
[TBL] [Abstract][Full Text] [Related]
24. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
25. Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/β‑catenin/N‑cadherin axis.
Kim CJ; Terado T; Tambe Y; Mukaisho KI; Kageyama S; Kawauchi A; Inoue H
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982789
[TBL] [Abstract][Full Text] [Related]
26. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer.
Tambe Y; Terado T; Kim CJ; Mukaisho KI; Yoshida S; Sugihara H; Tanaka H; Chida J; Kido H; Yamaji K; Yamamoto T; Nakano H; Omura S; Inoue H
Mol Carcinog; 2019 Oct; 58(10):1726-1737. PubMed ID: 31106493
[TBL] [Abstract][Full Text] [Related]
28. Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes.
Tao R; Xiong X; Harris RA; White MF; Dong XC
PLoS One; 2013; 8(8):e71997. PubMed ID: 23940800
[TBL] [Abstract][Full Text] [Related]
29. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.
Perez-Riverol Y; Bai J; Bandla C; García-Seisdedos D; Hewapathirana S; Kamatchinathan S; Kundu DJ; Prakash A; Frericks-Zipper A; Eisenacher M; Walzer M; Wang S; Brazma A; Vizcaíno JA
Nucleic Acids Res; 2022 Jan; 50(D1):D543-D552. PubMed ID: 34723319
[TBL] [Abstract][Full Text] [Related]
30. ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer.
Sugiura R; Satoh R; Takasaki T
Cells; 2021 Sep; 10(10):. PubMed ID: 34685488
[TBL] [Abstract][Full Text] [Related]
31. PPFIBP1 induces glioma cell migration and invasion through FAK/Src/JNK signaling pathway.
Dong C; Li X; Yang J; Yuan D; Zhou Y; Zhang Y; Shi G; Zhang R; Liu J; Fu P; Sun M
Cell Death Dis; 2021 Sep; 12(9):827. PubMed ID: 34480020
[TBL] [Abstract][Full Text] [Related]
32. Increased Expression of PDK4 Was Displayed in Gastric Cancer and Exhibited an Association With Glucose Metabolism.
Liu B; Zhang Y; Suo J
Front Genet; 2021; 12():689585. PubMed ID: 34220962
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
34. LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.
Zhou M; Kong Y; Wang X; Li W; Chen S; Wang L; Wang C; Zhang Q
Biomed Res Int; 2021; 2021():5561569. PubMed ID: 33728331
[TBL] [Abstract][Full Text] [Related]
35. α-Pinene Enhances the Anticancer Activity of Natural Killer Cells via ERK/AKT Pathway.
Jo H; Cha B; Kim H; Brito S; Kwak BM; Kim ST; Bin BH; Lee MG
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440866
[TBL] [Abstract][Full Text] [Related]
36. Bladder Cancer: A Review.
Lenis AT; Lec PM; Chamie K; Mshs MD
JAMA; 2020 Nov; 324(19):1980-1991. PubMed ID: 33201207
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
